Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice

Emanuela Palmerini, Kunhua Fan, Kan Yang, Mauro Risio, Winfried Edelmann, Martin Lipkin, Guido Biasco

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Background: The present study examines the effect of piroxicam, a non-steroidal anti-inflammatory drug, on tumor development in Mlh1 +/-/Apc1638N/+ mice, in a preclinical model of human colon cancer. Materials and Methods: Mice were fed AIN-76A diet alone or premixed with piroxicam (60 ppm) for 9 weeks. The number, location and volume of tumors, and apoptosis in the flat mucosa were determined in small and large intestine. Results: Piroxicam reduced the number of tumors per mouse by 80% in the small intestine (0.1 vs. 0.5, p<0.05). In contrast, piroxicam increased tumor incidence (82% vs. 10%, p<0.01), tumor multiplicity (1.2 vs. 0.1, p<0.01) and tumor volume (2.1 vs. 0.2 mm3, p<0.01) in the colon. Apoptosis increased in the epithelium of the small intestine. Conclusion: Consistent with the increased apoptosis, piroxicam reduced tumors in the small intestine. In the cecum, piroxicam increased tumorigenesis but apoptosis was not decreased, suggesting that other mechanisms besides apoptosis are involved in the differential organ-specific effect on tumorigenesis of piroxicam in this colon cancer model.

Original languageEnglish (US)
Pages (from-to)3807-3812
Number of pages6
JournalAnticancer Research
Issue number6 B
StatePublished - Nov 1 2007


  • Apc
  • Apoptosis
  • Chemoprevention
  • Colon cancer
  • Mlh1
  • Non-steroidal anti-inflammatory drugs

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Piroxicam increases colon tumorigenesis and promotes apoptosis in Mlh1 +/-/Apc1638N/+ mice'. Together they form a unique fingerprint.

Cite this